TY - JOUR
T1 - Identification and saturable nature of signaling pathways induced by metreleptin in humans
T2 - Comparative evaluation of in vivo, ex vivo, and in vitro administration
AU - Moon, Hyun Seuk
AU - Huh, Joo Young
AU - Dincer, Fadime
AU - Schneider, Benjamin E.
AU - Hasselgren, Per Olof
AU - Mantzoros, Christos S.
N1 - Funding Information:
This work was supported by the National Institutes of Health (DK- 081913) and a VA Merit award. The Mantzoros Laboratory is also supported by a discretionary grant from Beth Israel Deaconess Medical Center.
Publisher Copyright:
© 2015 by the American Diabetes Association.
PY - 2015/3
Y1 - 2015/3
N2 - Signaling pathways activated by leptin in metabolically important organs have largely been studied only in animal and/or cell culture studies. In this study, we examined whether leptin has similar effects in human peripheral tissues in vivo, ex vivo, and in vitro and whether the response would be different in lean and obese humans. For in vivo leptin signaling, metreleptin was administered and muscle, adipose tissue, and peripheral blood mononuclear cells were taken for analysis of signal activation. Experiments were also done ex vivo and with primary cultured cells in vitro. The signal activation was compared between male versus female and obese versus lean humans. Acute in vivo, ex vivo, and/or in vitro metreleptin administration similarly activated STAT3, AMPK, ERK1/2, Akt, mTOR, NF-κB, and/or IKKα/β without any differences between male versus female and obese versus lean subjects. All signaling pathways were saturable at ∼30-50 ng/mL, consistent with the clinical evidence showing no additional effect(s) in obese subjects who already have high levels of leptin. Our data provide novel information on downstream effectors of metreleptin action in humans that may have therapeutic implications.
AB - Signaling pathways activated by leptin in metabolically important organs have largely been studied only in animal and/or cell culture studies. In this study, we examined whether leptin has similar effects in human peripheral tissues in vivo, ex vivo, and in vitro and whether the response would be different in lean and obese humans. For in vivo leptin signaling, metreleptin was administered and muscle, adipose tissue, and peripheral blood mononuclear cells were taken for analysis of signal activation. Experiments were also done ex vivo and with primary cultured cells in vitro. The signal activation was compared between male versus female and obese versus lean humans. Acute in vivo, ex vivo, and/or in vitro metreleptin administration similarly activated STAT3, AMPK, ERK1/2, Akt, mTOR, NF-κB, and/or IKKα/β without any differences between male versus female and obese versus lean subjects. All signaling pathways were saturable at ∼30-50 ng/mL, consistent with the clinical evidence showing no additional effect(s) in obese subjects who already have high levels of leptin. Our data provide novel information on downstream effectors of metreleptin action in humans that may have therapeutic implications.
UR - http://www.scopus.com/inward/record.url?scp=84962110354&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84962110354&partnerID=8YFLogxK
U2 - 10.2337/db14-0625
DO - 10.2337/db14-0625
M3 - Article
C2 - 25249580
AN - SCOPUS:84962110354
SN - 0012-1797
VL - 64
SP - 828
EP - 839
JO - Diabetes
JF - Diabetes
IS - 3
ER -